Back to search results

Understanding GATTEX Use for Short Bowel Syndrome

This study is a survey to understand how well patients and doctors know how to use the medicine GATTEX and its possible risks. GATTEX is used to treat Short Bowel Syndrome (SBS). This survey is part of a safety program required by the FDA (US health authority) to make sure medicines with serious risks are used as safely as possible. You can join if you are 18 or older and have taken GATTEX in the last 60 days. A caregiver can also take the survey for an eligible patient who can't do it themselves. The study will measure how many correct answers participants and prescribers give to survey questions.

Study design
This is an observational study, meaning no intervention is given. It aims to enroll 600 participants.
What's involved
You would complete a survey. The trial record does not specify how long this would take.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures responses up to 18 years, but this refers to the age of participants, not the follow-up duration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05561647

A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)

Recruiting
Not specifiedAges 18+Observational
Takeda
~600 participants
Updated 2026-01-26 on ClinicalTrials.gov
What's tested:No Intervention

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants and Prescribers Providing Correct Responses to Questions
Measured over Up to 18 years

Conditions

Short Bowel Syndrome (SBS)

Explore related trials

Short Bowel Syndrome

NCT05561647

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Takeda Pharmaceuticals, U.S.A., Inc.

    Cambridge, Massachusettsno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Study Director · STUDY_DIRECTOR · Takeda

Who to contact

Takeda Contact
[email protected]
+1-877-825-3327
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Respondents who do not agree to participate in the survey.
Respondents who are currently working for and/or whose immediate family members who are currently working for Takeda Pharmaceuticals U.S.A., Inc., NPS Pharmaceuticals, Inc., Shire, UBC, or the Food and Drug Administration (FDA) are not eligible to participate in the survey.
Respondents who reported having a conflict of interest.
HCPs who have opted out of receiving communications about the GATTEX Prescriber Knowledge Assessment Survey for the current wave

What this trial measures

  • Number of Participants and Prescribers Providing Correct Responses to QuestionsUp to 18 years

    All questions for survey knowledge domain and about GATTEX will be asked through a questionnaire, Participant or HCPs would need to respond true or false to each question based upon understanding and knowledge. Respondents could be participants or HCPs.